Loading

Review Article Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/neurobiology.4.022

Systematic evaluation of the effects of exenatide and liraglutide on neurodegenerative diseases induced by type 2 diabetes mellitus

  • 1Republic of Turkey, Ministry of Health, Dr. Ismail Fehmi Cumalioglu City Hospital, Unit of Pharmacovigilance, and Rational Use of Drugs, Tekirdag, 59020, Turkey
  • 2Istanbul Rumeli University, Vocational School of Health Services, Department of Medical Services and Techniques, Istanbul, 34570, Turkey
  • 3Clinics of Endocrinology and Metabolic Diseases, Republic of Turkey, Ministry of Health, Doctor Ismail Fehmi Cumalioglu City Hospital, Tekirdag, 59100, Turkey
  • 4Department of Internal Medicine, Namik Kemal University School of Medicine, Tekirdag, 59100, Turkey
  • 5Halic University School of Medicine, Department of Neurosurgery, Istanbul, 34445, Turkey
  • 6Istanbul Rumeli University, Corlu Reyap Hospital, Clinics of Neurosurgery, Tekirdag, 59860, Turkey
  • 7Izmir Bakircay University School of Medicine, Department of Medical Pharmacology, Izmir, 35665, Turkey
  • 8Clinics of Neurosurgery, Kadikoy Medicana Hospital, Istanbul, 34724, Turkey
  • 9Department of Neurosurgery, Koc University School of Medicine, Istanbul, 34010, Turkey
+ Affiliations - Affiliations

Corresponding Author

Ibrahim Y?lmaz, dryilmazi@yahoo.com

Received Date: August 08, 2022

Accepted Date: August 18, 2022

Abstract

Currently, there are no effective treatment methods for Alzheimer's disease (AD), Parkinson's disease (PD), and olfactory dysfunction (OD). Given common pathophysiological features of neurodegenerative diseases such as AD and type 2 diabetes mellitus (T2DM), antidiabetic drugs such as exenatide and liraglutide, which act as incretin mimetics, are tested as a potential treatment option. This systematic review aimed to evaluate the effects of exenatide and liraglutide pharmaceuticals on amyloid-beta (Aβ)/tau protein and cognition in patients with AD, PD, OD, and concomitant T2DM. Randomized controlled clinical trials were retrieved from electronic databases using a combination of relevant MeSH keywords, and the retrieved studies were evaluated. Results were presented as the number in the relevant date range. No randomized, controlled, clinical trial in which exenatide or liraglutide was administered to patients with PD and T2DM was found. Four studies that examined the effects of these two drugs on patients with T2DM and PD were retrieved. One study that investigated the effects of exenatide or liraglutide on patients with T2DM and OD was extracted. Currently, there are no incretin mimetics agents that can improve the pathophysiology of neurodegenerative diseases such as AD, PD, OD, and concomitant T2DM and that can be used in the treatment of these diseases. For these pharmacological agents to be included in the routine treatment algorithm of neurodegenerative diseases accompanied by T2DM, further multicenter, randomized clinical trials including a larger number of cases are needed.

Keywords

Alzheimer's Disease, Brain, Exenatide, Glucagon-Like Peptide 1, Liraglutide

Author Information X